Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vomiting 9Nausea 5Breast Neoplasms 4Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms, Germ Cell and Embryonal 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1

Interventions

Cisplatin 4Etoposide 3Carboplatin 3etoposide phosphate 2Paclitaxel 2Bleomycin 2pralsetinib 1pembrolizumab 1pegfilgrastim 1Standard of Care 1Specimen Handling 1Respiratory Physiological Phenomena 1Practice Guidelines as Topic 1Platinum 1Pemetrexed 1Magnetic Resonance Spectroscopy 1Injections 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1Biopsy 1Aprepitant 1130-nm albumin-bound paclitaxel 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasms, Germ Cell and Embryonal × Aprepitant × Clear all
NCT00572572 2016-04-06

Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors

Hoosier Cancer Research Network

Phase 3 Completed
69 enrolled 14 charts

Neoplasms, Germ Cell and Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡